# Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

> **NCT07363265** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Longbio Pharma** · enrollment: 46 (estimated)

## Conditions studied

- Complement-mediated Renal Diseases

## Interventions

- **BIOLOGICAL:** LP-005 Injection

## Key facts

- **NCT ID:** NCT07363265
- **Lead sponsor:** Longbio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2028-08-02
- **Final completion:** 2029-05-02
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363265, "Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07363265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*